Tempest Therapeutics Q3 net loss per share narrows on lower R&D expenses

By Reuters News


Overview

  • US biotech firm posted Q3 net loss per share of $0.21, narrower than prior year

  • Company ended Q3 with $0.9 mln in cash, down from $7.7 mln at year-end 2025


Outlook

  • Company expects to present initial data from TPST-4903 Phase 1 study at upcoming conference

  • Investigator-initiated trial for TPST-4003 in myasthenia gravis or multiple sclerosis to begin Q4 2026

  • Company says existing cash expected to fund operations for less than 12 months


Result Drivers

  • R&D SPENDING SHIFT - Research and development expenses fell due to portfolio reprioritization after asset acquisition, offset by costs related to CAR-T candidates

  • HIGHER FINANCING COSTS - Financing costs rose due to commitment shares and issuance costs related to the Lincoln Park equity line of credit

  • PIPELINE ADVANCEMENT - Company cited progress in expanding its CAR-T pipeline and securing exclusive licensing agreements


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.21


Reuters Recommended Reads

  • Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall

  • Nov 12 - Prime Medicine Q3 loss narrows as expenses decline

  • Nov 13 - PDS Biotechnology Q3 net loss narrows on lower R&D costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.